Blinatumomab Trimer Formation
Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…
CertaraSeptember 16, 2024
4 ways that mechanistic modeling accelerates bispecific (and multispecific) antibody drug development
With nine FDA-approved drugs today, 100+ in clinical development and several hundred in the preclinical…
CertaraSeptember 12, 2024
Dose Selection for DuoBody®-PD-L1x4-1BB (GEN1046)
Abstract DuoBody®-PD-L1x4-1BB (GEN1046) is an investigational, first-in-class, bispecific antibody designed to elicit an antitumor immune…
CertaraSeptember 9, 2024
Optimizing Avidity of Bispecific Drugs
Abstract Bispecific drugs have great potential to improve tissue selectivity through avid binding interactions but…
CertaraSeptember 9, 2024
Effects of Tissue Targeting Bispecifics on Therapeutic Window
Abstract Objectives: The presence of target receptors in non-target tissues can reduce the therapeutic window…
CertaraSeptember 9, 2024
Optimizing Clinical Development: Saving Time and Costs
Strategic mechanistic modeling solutions help an immunoncology biotech accelerate their clinical development of novel therapeutics.
CertaraAugust 16, 2024
Dosing Strategies and Quantitative Clinical Pharmacology for Bispecific T-Cell Engagers Development in Oncology
Bispecific T-cell Engagers (TCEs) are promising anti-cancer treatments that bind to both the CD3 receptors…
CertaraJuly 23, 2024
Gene therapy based precision medicine therapeutics: Clinical pharmacology & translational science considerations
The era of gene therapy may have started a couple of decades ago, but approvals…
CertaraAugust 13, 2021
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines
Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due…
CertaraJuly 31, 2021
